Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets through a merger with Brookline Capital Acquisition Corp., a blank-check vehicle sponsored by an affiliate of Brookline Capital Markets that completed its initial public offering in 2021. The S-1/A registration statement filed with the SEC on September 1, 2022, under accession number 0001193125-22-236626, reflects the combined entity following the de-SPAC transaction. Apexigen's pipeline centers on antibody-based cancer immunotherapies, including its lead candidate sotigalimab, a CD40 agonist antibody evaluated across multiple solid tumor indications. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal timelines on APGN and the broader SPAC universe.